Key facts
- This page summarizes A. J. Kazimi's Form 4 filing for CUMBERLAND PHARMACEUTICALS INC (CPIX).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 20 Mar 2026, 17:19.
A. J. Kazimi - 18 Mar 2026 Form 4 Insider Report for CUMBERLAND PHARMACEUTICALS INC (CPIX)
- Reporting relationship
- Chairman and CEO, Director, 10%+ Owner
- Issuer ticker
- CPIX
- Reported as of
- 18 Mar 2026
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 20 Mar 2026, 17:19:28 UTC
- Prior SEC filing
- 18 Mar 2026
- Source filing
- View source filing
- Reporting owner signature
- A.J. Kazimi by /s/ John Hamm as attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
A. J. Kazimi filed Form 4 for CUMBERLAND PHARMACEUTICALS INC (CPIX) on 20 Mar 2026.
Change
- Previous filing in this sequence was filed on 18 Mar 2026.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001075050
Primary reporting owner
KAZIMI A J
- Relationship
- Chairman and CEO, Director, 10%+ Owner
- Address
- 1600 WEST END AVE., SUITE 1300, NASHVILLE
- Signature
- A.J. Kazimi by /s/ John Hamm as attorney-in-fact
- Signature date
- 20 Mar 2026
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CPIX
transaction
Derivative
Options (right to buy)
Award
- Transaction value
- Shares
- +100,000
- Change %
- +21%
- Price
- $2.80*
- Shares after
- 568,000
- Date
- 18 Mar 2026
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 100,000
- Exercise price
- $2.80
* marks a reported price that did not pass the local price check.